InMed Pharmaceuticals (IMLFF) is a small-cap pre-clinical stage Canadian pharmaceutical company "focused on the therapeutic potential of cannabinoids" (i.e. the constituents of marijuana). InMed, despite its small size, is one of the more scientifically advanced companies in the area of medical marijuana research. The company has developed a "bioinformatics" software system to facilitate drug design and has three pre-clinical stage cannabinoid drugs in its pipeline. However, neither the bioinformatics package nor their drug pipeline is what makes this company interesting and unique. What makes them interesting and unique is their development of a biosynthesis process